Scientific & Clinical Advisory Board
Edith Mathiowitz, Ph.D.
Dr. Mathiowitz is tenured Professor of Medical Science and Engineering, and the Director of the Artificial Organs, Biomaterials and Cellular Technology graduate program at Brown University’s Department of Molecular Pharmacology, Physiology & Biotechnology. She received her Ph.D. in Polymer Chemistry from the Weizmann Institute of Science in Israel and did her Post-doctoral fellowship in drug delivery with Professor Robert Langer at MIT. Dr. Mathiowitz is the Inventor and co-Inventor of Therapyx’s core patents licensed from Brown University. She worked at Enzytech (now Alkermes) and was one of the developers of the Prolease® drug delivery technology. Dr. Mathiowitz founded Spherics Inc. in 1997 and served as its Chairperson and Member of its Scientific Advisory Board. She served as a 2005 co-chair of the Controlled Release Society, the leading international organization on drug delivery. Dr. Mathiowitz founded Perosphere Inc. in 2011 and served as its Chief Scientific Officer. She also currently serves as a Member of the Scientific Advisory Board of Perosphere and Freedom-2, Inc. Dr. Mathiowitz has played a critical role in the development of Therapyx‘s EXStaM (Patent Pending) technology.
Scott A. Gerber, Ph.D.
Dr. Gerber is a tumor immunologist and NIH-funded investigator with expertise in cancer immunology and translational therapeutic development. His research is focused on stimulating the immune system to mount more effective anti-tumor responses and on developing novel strategies to overcome immune suppression in the tumor microenvironment. He is Director of the Center for Tumor Immunology Research, Program Leader of the Cancer Microenvironment Program at Wilmot Cancer Institute, and Co-Director of the Immunology T32 Training Program, reflecting both his scientific leadership and strong commitment to mentoring trainees. Dr. Gerber leads a highly collaborative research program aimed at advancing innovative immune-based therapies for pancreas cancer and translating promising discoveries toward clinical impact.
Neal Bhutiani, M.D., Ph.D.
Dr. Bhutiani is an immunologist and board-certified surgical oncologist whose research and clinical practice both focus on primary and metastatic colon and rectal cancer. He earned his MD from Johns Hopkins University and PhD in Microbiology and Immunology from the University of Louisville. He completed his clinical residency in General Surgery at the University of Louisville and clinical fellowships in Complex General Surgical Oncology and Advanced Colorectal Surgical Oncology at the University of Texas MD Anderson Cancer Center. He currently is an Assistant Professor in Surgery and Microbiology and Immunology at the University of Louisville, where he serves as the Jewish Hospital Distinguished Professor in Tumor Immunology. His laboratory studies the interplay between the local and systemic immune system, microbes, metabolites, and tumor cells in colon and rectal cancer to identify strategies to improve response to current therapy and identify new therapies for this disease.
Ferdinando Nicoletti, M.D
Dr. Nicoletti is a Full Professor of General Pathology and Immunology at the School of Medicine of the University of Catania, Italy. He has also served for several years as external consultant at the Institute for Inflammation Research at Copenhagen University Hospital (Rigshospitalet) He is a recognized expert in the discovery and development of new drugs for the treatment of cancer and inflammatory diseases. Prof. Nicoletti serves and has served as an advisor to and collaborator with leading pharmaceutical companies including Amgen, MerckSerono, Leo Pharma, Novozyme and Pfizer, that led to the clinical development of anti-cancer and immunomodulatory drugs. Prof. Nicoletti has published more than 250 papers in peer reviewed scientific journals, achieving HI of 60 (google scholar). He is inventor of 7 patents, and he is on the editorial board of several international journals including European Journal of Pharmacology, Basic and Clinical Pharmacology and Toxicology, International Journal of Oncology, Molecules and Brain Sciences. He serves on the board of directors of several biotechnology companies.
